Photo: Reuters
LONDON (Reuters) - Days after grabbing headlines with its COVID-19 "vaccine for the world", AstraZeneca is facing tricky questions about its success rate that some experts say could hinder its chances of getting speedy U.S. and E.U. regulatory approval.
Several scientists have raised doubts about the robustness of results showing the shot was 90% effective in a sub-group of trial participants who, by error initially, received a half dose followed by a full dose.
British drugmaker AstraZeneca said on Monday that its experimental vaccine, developed with Oxford University, prevented on average 70% of COVID-19 cases in late-stage trials in Britain and Brazil.
While the success rate was 90% in the sub-group of volunteers, the efficacy was 62% if the full dose was given twice, as it was for most participants.
That is well above the 50% efficacy required by U.S. regulators. Europe's drug regulator has said it will not set a minimum level of efficacy for potential vaccines.
The U.S. regulator, the Food and Drug Administration (FDA), has not commented on AstraZeneca's vaccine trial results.
The European Medicines Agency said on Thursday it would "assess data on the efficacy and safety of the vaccine in the coming weeks once they have been received from the company".
Read more from the original article:
편집됨
면책 조항: 본 게시글에 표현된 견해는 전적으로 작성자의 견해이며 Followme의 공식 입장을 대변하지 않습니다. Followme는 제공된 정보의 정확성, 완전성 또는 신뢰성에 대해 책임을 지지 않으며, 서면으로 명시적으로 언급되지 않는 한 해당 내용을 기반으로 취해진 어떠한 조치에 대해서도 책임을 지지 않습니다.
더 오래된 의견은 없습니다. 소파를 가장 먼저 잡으십시오.